CLINICAL_TRIALS
trial_result
· 2025-04-22
Clinical Trial Update: Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients [Phase 2]
Summary
Phase 2 trial update for simufilam (PTI-125) at 100 mg is completed with results posted for patients with mild-to-moderate Alzheimer disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cassava Sciences, Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-04-22